je.st
news
Tag: biotechs
Wall Street dips as biotechs sink Nasdaq
2015-03-26 09:08:25| Biotech - Topix.net
US stocks dropped on Wednesday as a slump in technology and biotechs sent the Nasdaq to its biggest decline in nearly a year while the S&P 500 fell through key support levels. Semiconductors and biotech stocks weighed heavily on the Nasdaq, suffering their third straight session of declines after strong gains in the prior week.
Tags: street
wall
wall street
nasdaq
Ligand Pharmaceuticals: Biotech's Jack Of All Trades
2015-03-26 00:46:06| Biotech - Topix.net
"We do early-stage development, and we aim to partner early," said Matt Foehr, president and chief operating officer. "We keep a flat operating structure, and we enjoy royalties on the back."
Tags: jack
trades
pharmaceuticals
ligand
1 Tiny Biotech's Blockbuster Opportunity in Heart Disease
2015-03-23 00:02:59| Biotech - Topix.net
The U.S. Food and Drug Administration approved the first cholesterol-busting statin drug more than 20 years ago, and statins' proven ability to cut cholesterol levels has turned them into the most widely used drugs in America. However, for millions of people statin therapy alone fails, and that's why Esperion Therapeutics Lipitor every year, heart disease remains the No.
Tags: heart
opportunity
disease
tiny
3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
2015-03-01 17:35:43| Biotech - Topix.net
Revlimid was already on pace to deliver sales of more than $5 billion this year as the leading second-line treatment for the indication; the FDA and EU's approval for its use in newly diagnosed patients could mean that sales finish 2015 closer to an annualized $6 billion pace than a $5 billion pace. Celgene should also be able to notch solid sales growth from its third-line multiple myeloma drug Pomalyst and its cancer drug Abraxane.
Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer
2015-02-17 15:06:44| Biotech - Topix.net
Oncolytics Biotech Inc. , a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. "This is the second indication for which we have received Orphan Drug Designation in the United States," said Dr. Brad Thompson, President and CEO of Oncolytics.
Tags: treatment
drug
cancer
receives
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] next »